Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07565155 · ClinicalTrials.gov registry record · Phase 2
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency
A Phase 2 study, sponsored by Peter Hosein, MD.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT07565155 is a Phase 2 study that has not yet begun recruiting, run by Peter Hosein, MD. The registered enrollment target is 40 participants.
The verdict
NCT07565155, a Phase 2 study, has not yet begun recruiting, sponsored by Peter Hosein, MD.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the objective response rate (ORR) to lorigerlimab in patients with refractory pancreatic ductal adenocarcinoma (PDAC) and pathogenic germline variants (PGVs) in breast cancer type 1 or 2 susceptibility protein (BRCA1/2), Partner and Localizer of BRCA2 (PALB2) and radiation sensitive protein 51 C or D (RAD51C/D).
Interventions
- DRUG Lorigerlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2031-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07565155
The ClinicalTrials.gov registry entry for NCT07565155 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peter Hosein, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lorigerlimab is the first listed.
NCT07565155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07565155 about?
NCT07565155 is a clinical study titled "Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency". The purpose of this study is to determine the objective response rate (ORR) to lorigerlimab in patients with refractory pancreatic ductal adenocarcinoma (PDAC) and pathogenic germline variants (PGVs) in breast cancer type 1 or 2 susceptibility protein (BRCA1/2), Partner and Localizer of BRCA2 (PALB2...
What is the current status of trial NCT07565155?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-06-01. Estimated completion is 2031-06-01.
What interventions are being tested in trial NCT07565155?
The interventions under investigation include: Lorigerlimab (DRUG).
Who is sponsoring clinical trial NCT07565155?
This trial is sponsored by Peter Hosein, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.